Summit Therapeutics

BioNTech to buy Biotheus, gaining control of cancer bispecific
BioPharma Dive
Wed, 11/13/24 - 11:30 am
BioNTech
M&A
Biotheus
Summit Therapeutics
cancer bispecifics
Ivonescimab Looking to Rival Merck’s Keytruda in NSCLC with Phase III Trial Enrollment Complete
Xtalks
Thu, 10/10/24 - 10:02 am
Summit Therapeutics
ivonescimab
non-small cell lung cancer
clinical trials
Merck
Keytruda
Keytruda beaten by Summit’s bispecific in NSCLC
Clinical Trials Arena
Fri, 09/20/24 - 11:15 am
Summit Therapeutics
Akeso
Merck
clinical trials
ivonescimab
Keytruda
non-small cell lung cancer
Summit lung cancer drug shows ‘striking’ benefit over Keytruda
BioPharma Dive
Sun, 09/8/24 - 11:32 pm
Summit Therapeutics
Merck
Keytruda
clinical trials
non-small cell lung cancer
Summit Raises $200 Million; Also Expands License Territories for Ivonescimab
BioSpace
Mon, 06/3/24 - 12:02 pm
Summit Therapeutics
ivonescimab
funding
Summit makes case for changes to antibiotic R&D after sharing data from failed phase 3 trial
Fierce Biotech
Fri, 10/21/22 - 10:59 am
Summit Therapeutics
clinical trials
R&D
antibiotic
Summit will take scenic route up FDA mountain after regulator recommends more trials for C. diff therapy
Fierce Biotech
Thu, 07/14/22 - 07:51 pm
Summit Therapeutics
ridinilazole
C. difficile
Summit says path forward for failed C. difficile drug is likely through partnerships
Fierce Biotech
Sun, 03/20/22 - 10:52 pm
Summit Therapeutics
Vancomycin
clinical trials
C. difficile
Summit’s Ridinilazole Preserved the Gut Microbiome of Patients with C. difficile in Ph II Trial
CP Wire
Fri, 08/3/18 - 11:04 am
Summit Therapeutics
C. difficile
microbiome ridinilazole
Summit Therapeutics Ditches Duchenne Drug In Wake of Phase 2 Failure
Xconomy
Wed, 06/27/18 - 11:56 am
Summit Therapeutics
ezutromid
clinical trials
Duchenne Muscular Dystrophy
Data from trials could send these clinical-stage biotech stocks soaring or crashing
Motley Fool
Mon, 02/5/18 - 08:26 am
clinical trials
biotech
Summit Therapeutics
DMD
Jounce Therapeutics
JTX-2011
TG Therapeutics
ublituximab
How the newest Duchenne biotechs are getting a boost from patient groups
Bizjournals.com
Mon, 02/27/17 - 09:15 am
patients
patient groups
Duchenne Muscular Dystrophy
Sarepta Therapeutics
Santhera
Catabasis
Akashi Therapeutics
Summit Therapeutics
Solid Biosciences
Sarepta Wins Exclusive License, Collaboration Deal for European Rights To Summit's DMD Drug
Yahoo/Benzinga
Tue, 10/4/16 - 03:58 pm
Sarepta Therapeutics
Europe
Duchenne Muscular Dystrophy
Summit Therapeutics
ezutromid
Sarepta: The Competition Is At The Gate
Seeking Alpha
Fri, 08/12/16 - 09:53 am
Sarepta Therapeutics
eteplirsen
Biomarin
Summit Therapeutics
PTC Therapeutics
Duchenne Muscular Dystrophy
Summit develops a unique Duchenne drug for any gene mutation
Bizjournals.com
Sat, 03/26/16 - 12:59 pm
Summit Therapeutics
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Summit pulls off a downsized IPO for its DMD drug
Fierce Biotech
Thu, 03/5/15 - 08:55 am
Duchenne Muscular Dystrophy
Summit Therapeutics
SMT C1100
IPOs